This phase I trial will evaluate different doses of a new cancer drug (RO7425781) for the treatment of multiple myeloma patients who cannot tolerate other treatment options or for whom no standard treatment is available.
This trial is treating patients with multiple myeloma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
An Open-Label, Multicenter, Phase I Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of RO7425781 in Participants With Relapsed or Refractory Multiple Myeloma
This trial will be conducted in two parts: Dose-escalation (Part 1) and randomised Dose Expansion (Part 2). Eligible patients will receive intravenous and/or subcutaneous RO7425781 either in a set up dosing fashion (Part 1) or at the maximum tolerated/Recommended Phase 2 Dose (Part 2).
Recruiting Hospitals Read More